ArticleOncology and therapy2018

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.

Edgardo S Santos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.